Ruxolitinib, a JAK1/JAK2 inhibitor (13), has shown clinical benefits in polycythemia vera (PV) patients which carry an activity mutation of JAK2 gene (i.e., V617F) (14–16). The gene discussed is JAK1; the disease is acquired polycythemia vera.